[go: up one dir, main page]

BR112014012409B8 - Composições de buprenorfina e antagonistas do receptor mu-opioide - Google Patents

Composições de buprenorfina e antagonistas do receptor mu-opioide

Info

Publication number
BR112014012409B8
BR112014012409B8 BR112014012409A BR112014012409A BR112014012409B8 BR 112014012409 B8 BR112014012409 B8 BR 112014012409B8 BR 112014012409 A BR112014012409 A BR 112014012409A BR 112014012409 A BR112014012409 A BR 112014012409A BR 112014012409 B8 BR112014012409 B8 BR 112014012409B8
Authority
BR
Brazil
Prior art keywords
buprenorphine
opioid receptor
compositions
receptor antagonists
composition
Prior art date
Application number
BR112014012409A
Other languages
English (en)
Other versions
BR112014012409A2 (pt
BR112014012409B1 (pt
Inventor
Deaver Daniel
Ehrich Elliot
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of BR112014012409A2 publication Critical patent/BR112014012409A2/pt
Publication of BR112014012409B1 publication Critical patent/BR112014012409B1/pt
Publication of BR112014012409B8 publication Critical patent/BR112014012409B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÕES DE BUPRENORFINA E ANTAGONISTAS DO RECEPTOR MU-OPIÓIDE. A invenção refere-se a uma composição que compreende a buprenorfina e um antagonista do receptor micro-opioide, em que a composição é caracterizada por um Índice de Atividade Agonista:Antagonista (AAnAI) de entre cerca de 0,7 e cerca de 2,2; em que (Fórmula).
BR112014012409A 2011-12-15 2012-12-14 Composições de buprenorfina e antagonistas do receptor mu-opioide BR112014012409B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161576233P 2011-12-15 2011-12-15
US61/576,233 2011-12-15
PCT/IB2012/002900 WO2013088243A1 (en) 2011-12-15 2012-12-14 Compositions of buprenorphine and mu-opioid receptor antagonists

Publications (3)

Publication Number Publication Date
BR112014012409A2 BR112014012409A2 (pt) 2017-06-13
BR112014012409B1 BR112014012409B1 (pt) 2022-08-23
BR112014012409B8 true BR112014012409B8 (pt) 2022-09-13

Family

ID=47757653

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012409A BR112014012409B8 (pt) 2011-12-15 2012-12-14 Composições de buprenorfina e antagonistas do receptor mu-opioide

Country Status (25)

Country Link
US (8) US8822488B2 (pt)
EP (3) EP3415148A1 (pt)
JP (2) JP6038170B2 (pt)
KR (1) KR101996108B1 (pt)
CN (2) CN104159586A (pt)
AU (1) AU2012351806C1 (pt)
BR (1) BR112014012409B8 (pt)
CA (1) CA2858812C (pt)
CY (1) CY1121081T1 (pt)
DK (1) DK3153171T3 (pt)
EA (1) EA030609B8 (pt)
ES (2) ES2692771T3 (pt)
HR (1) HRP20181950T1 (pt)
HU (1) HUE041883T2 (pt)
IL (1) IL232785B (pt)
LT (1) LT3153171T (pt)
MX (2) MX391181B (pt)
PL (1) PL3153171T3 (pt)
PT (1) PT3153171T (pt)
RS (1) RS58322B1 (pt)
SI (1) SI3153171T1 (pt)
SM (1) SMT201800664T1 (pt)
TR (1) TR201815154T4 (pt)
WO (1) WO2013088243A1 (pt)
ZA (1) ZA201405029B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5691042B2 (ja) 2009-12-04 2015-04-01 アルカーメス ファーマ アイルランド リミテッド 薬物過量摂取の治療のためのモルヒナン誘導体
DK3446565T3 (da) 2010-08-23 2024-01-22 Alkermes Pharma Ireland Ltd Fremgangsmåder til behandling af antipsykotika-induceret vægtøgning
EA030609B8 (ru) 2011-12-15 2018-10-31 Алкермес Фарма Айэленд Лимитед Композиции бупренорфина и антагонистов мю-опиоидных рецепторов
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
US9133125B2 (en) 2013-05-24 2015-09-15 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
TW201636329A (zh) 2015-02-02 2016-10-16 佛瑪治療公司 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸
IL280856B (en) 2015-02-02 2022-09-01 Forma Therapeutics Inc 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH581624A5 (pt) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US4127577A (en) 1975-11-24 1978-11-28 Sterling Drug Inc. Aminomethanobenzazocine process
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US5258386A (en) 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
HUP9900974A3 (en) 1996-01-10 2000-09-28 Smithkline Beecham Spa Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
ES2572332T3 (es) 2000-10-31 2016-05-31 Rensselaer Polytech Inst 2,6-metano-3-benzazocinas sustituidas en posición 8 y morfinanos sustituidos en posición 3 como ligandos de receptores opioides
ES2305457T3 (es) * 2002-03-20 2008-11-01 Euro-Celtique S.A. Metodo de administracion de buprenorfina para tratar la depresion.
ES2249722T3 (es) 2002-05-30 2006-04-01 Eli Lilly And Company Antagonistas de receptor de opioides.
BRPI0511137A (pt) 2004-05-14 2007-11-27 Janssen Pharmaceutica Nv compostos opióides de carboxamido
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
CA2587074C (en) 2004-11-05 2012-09-04 Rensselaer Polytechnic Institute 4-hydroxybenzomorphans
PT1856093E (pt) 2005-03-02 2010-02-08 Nycomed Gmbh Sal hcl de (2r,4ar,10br)-6-(2,6-dimetoxipiridin-3-il)-9-etoxi- 8-metoxi-1,2,3,4,4a,10b-hexa-hidrofenantridin-2-ol
CN101677971A (zh) 2007-03-19 2010-03-24 阿卡蒂亚药品公司 5-ht2a反向激动剂和拮抗剂与抗精神病药物的组合
CA2694497C (en) 2007-08-09 2016-07-12 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
EP2252150B1 (en) * 2008-02-14 2018-04-11 Alkermes, Inc. Selective opioid compounds
WO2009126931A2 (en) * 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
WO2010107457A1 (en) * 2009-03-19 2010-09-23 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
US20120149724A1 (en) 2009-06-04 2012-06-14 The General Hospital Corporation Modulating endogenous beta-endorphin levels
US8530479B2 (en) * 2009-08-10 2013-09-10 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides
JP5691042B2 (ja) * 2009-12-04 2015-04-01 アルカーメス ファーマ アイルランド リミテッド 薬物過量摂取の治療のためのモルヒナン誘導体
US9211293B2 (en) * 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EA030609B8 (ru) 2011-12-15 2018-10-31 Алкермес Фарма Айэленд Лимитед Композиции бупренорфина и антагонистов мю-опиоидных рецепторов
US9656961B2 (en) * 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms

Also Published As

Publication number Publication date
CN104159586A (zh) 2014-11-19
EP3153171B1 (en) 2018-09-19
DK3153171T3 (en) 2018-11-19
EP3153171A1 (en) 2017-04-12
MX391181B (es) 2025-03-21
TR201815154T4 (tr) 2018-11-21
JP2015505853A (ja) 2015-02-26
RS58322B1 (sr) 2019-03-29
CY1121081T1 (el) 2019-12-11
JP2016222706A (ja) 2016-12-28
JP6403726B2 (ja) 2018-10-10
MX2014007042A (es) 2015-01-22
US20170056392A1 (en) 2017-03-02
CN106727562A (zh) 2017-05-31
MX375348B (es) 2025-03-06
US20180078543A1 (en) 2018-03-22
AU2012351806B2 (en) 2016-03-10
SI3153171T1 (sl) 2019-01-31
CA2858812C (en) 2019-02-26
WO2013088243A1 (en) 2013-06-20
SMT201800664T1 (it) 2019-01-11
US9918978B2 (en) 2018-03-20
US20160256450A1 (en) 2016-09-08
US9498474B2 (en) 2016-11-22
EA030609B1 (ru) 2018-08-31
US10188643B2 (en) 2019-01-29
EP2790702A1 (en) 2014-10-22
IL232785B (en) 2021-04-29
HUE041883T2 (hu) 2019-06-28
PL3153171T3 (pl) 2019-02-28
US20180078542A1 (en) 2018-03-22
CA2858812A1 (en) 2013-06-20
AU2012351806A1 (en) 2014-05-15
US9913837B2 (en) 2018-03-13
EA201491153A1 (ru) 2015-04-30
EA030609B8 (ru) 2018-10-31
KR20140107258A (ko) 2014-09-04
JP6038170B2 (ja) 2016-12-07
ES2692771T3 (es) 2018-12-05
BR112014012409A2 (pt) 2017-06-13
HRP20181950T1 (hr) 2019-03-22
US20150051240A1 (en) 2015-02-19
IL232785A0 (en) 2014-07-31
US20130190342A1 (en) 2013-07-25
KR101996108B1 (ko) 2019-10-01
CN106727562B (zh) 2019-07-05
EP3415148A1 (en) 2018-12-19
LT3153171T (lt) 2018-12-10
AU2012351806C1 (en) 2016-06-16
ES2791764T3 (es) 2020-11-05
US20210196703A1 (en) 2021-07-01
US10806731B2 (en) 2020-10-20
EP2790702B1 (en) 2020-04-01
US20190247387A1 (en) 2019-08-15
NZ624056A (en) 2016-07-29
US10314838B2 (en) 2019-06-11
BR112014012409B1 (pt) 2022-08-23
PT3153171T (pt) 2018-11-16
ZA201405029B (en) 2015-10-28
US8822488B2 (en) 2014-09-02

Similar Documents

Publication Publication Date Title
BR112014012409B8 (pt) Composições de buprenorfina e antagonistas do receptor mu-opioide
CY1123365T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MY173521A (en) Trpv4 antagonists
AU2011234398A8 (en) Novel NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
EP2934527A4 (en) 2-pyridyloxy-4-ESTER-orexin receptor antagonists
UA111640C2 (uk) ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
EP2925321A4 (en) 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
EP4268814A3 (en) Pharmaceutical composition for the treatment of dry eye
CL2013000732A1 (es) Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion.
MX2012012897A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta-2 y como antagonistas muscarinicos m3.
PH12014501057A1 (en) New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities
MX2014004387A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos b2 y como antagonistas muscarinicos m3.
GT201400086A (es) Compuestos con actividad nematicida
BR112015012746A2 (pt) compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
EA201490332A1 (ru) Соединения (тиено[2,3-b][1,5]бензоксазепин-4-ил)пиперазин-1-ила, обладающие двойной активностью обратных агонистов рецепторов h1/антагонистов рецепторов 5-ht
UA110039C2 (xx) СПОЛУКИ 4-ЗАМІЩЕНОГО 3-ФЕНІЛСУЛЬФАНІЛМЕТИЛБІЦИКЛО$3.1.0]ГЕКСАНУ ЯК АНТАГОНІСТИ mGluR 2/3
PH12012502300A1 (en) Nicotinic receptor non-competitive antagonists
WO2010054003A3 (en) Methylindazole modulators of 5-ht3 receptors
UA108104C2 (uk) ПОХІДНІ ЦИКЛОГЕКСИЛАМІНУ, ЩО МАЮТЬ АГОНІСТИЧНУ АКТИВНІСТЬ ПО ВІДНОШЕННЮ ДО β2 АДРЕНЕРГІЧНОГО РЕЦЕПТОРА І АНТАГОНІСТИЧНОЇ АКТИВНОСТІ ПО ВІДНОШЕННЮ ДО M3 МУСКАРИНОВОГО РЕЦЕПТОРА
TN2013000209A1 (en) 4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists
UA108659C2 (xx) Аналоги бупренорфіну
UA54879U (ru) Применение антагониста рецепторов интерлейкина-1 как средства антиоксидантного действия
PH12013501453A1 (en) Nicotinic receptor non-competitive antagonists

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/2012, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2694 DE 23/08/2022 QUANTO AO TITULO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2805 DE 08-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.